MindBio's AI Voice Analytics Achieves Up to 83% Accuracy in Intoxication Detection, Eyes Commercial Pilot

MindBio Therapeutics reports up to 83% accuracy in AI-driven intoxication detection and announces a CA$350,000 private placement to support commercialization.

Houston Metrowire Staff
••Technology
MindBio's AI Voice Analytics Achieves Up to 83% Accuracy in Intoxication Detection, Eyes Commercial Pilot

MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced that its artificial intelligence (AI)-driven voice analytics technology is nearing final product testing ahead of its first commercial pilot, with intoxication detection accuracy reaching up to 83% under certain testing conditions. The company reported that its prediction models, tested with and without sober baseline tracking, have exceeded the accuracy of some commercially available cheek swab tests. This development matters because it suggests a non-invasive, scalable alternative to traditional intoxication testing methods, with potential applications across industries such as mining, aviation, construction, and law enforcement.

MindBio plans to conduct additional human testing over the next two to three weeks before launching its first commercial pilot. The company expects its initial commercially ready product to integrate proprietary Voice AI software with its previously announced Edge AI Intoxication Detection Kiosk, initially operating in Spanish. The technology uses over 50 million data points to predict alcohol intoxication solely from the human voice, according to the company. If validated in real-world settings, this could enable faster, more efficient workplace and roadside screening, reducing reliance on invasive tests and specialized personnel.

Separately, MindBio announced a nonbrokered private placement of up to 3,888,889 units at $0.09 per unit for gross proceeds of up to CA$350,000. Each unit will consist of one common share and one-half of a common share purchase warrant, with each whole warrant exercisable at $0.16 per share for 36 months following closing. Proceeds are intended to support general working capital, annual audit and legal expenses, and OTC and CSE listing costs. The financing underscores the company's need for capital as it moves toward commercialization, and its success could affect the timeline for the pilot launch and broader market entry.

For investors, the announcement highlights both the promise and the risks of early-stage AI health technology. The reported accuracy, while encouraging, is based on internal testing and has yet to be independently verified. The private placement, priced at $0.09 per unit, may also signal the company's current valuation and funding needs. MindBio is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis, and its enterprise platform includes Edge-AI kiosks integrating bespoke hardware and software for detection in a range of enterprise environments. The full press release is available at https://ibn.fm/ErHN1, and the latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF.

The announcement was disseminated through TechMediaWire, a specialized communications platform focused on pioneering public and private companies driving the future of technology. TechMediaWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. The broader implication is that AI-based voice analytics could reshape how workplaces and authorities approach intoxication screening, but regulatory acceptance, privacy considerations, and independent validation will determine whether MindBio's technology can achieve widespread adoption.

Blockchain Registration

QR Code for Blockchain Registration